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THE IMPACT OF FAMILY HISTORY ON MEDULLARY THYROID CANCER IN
MEN2A PATIENTS
Publication No. ____________________
Nicole D. Mohrbacher, MS
Supervisory Professor: Thereasa Rich, MS, CGC
The American Thyroid Association recently classified all MEN2A-associated codons
into increasing risk levels A-C and stated that some patients may delay prophylactic
thyroidectomy if certain criteria are met. One criterion is a less aggressive family history of
MTC but whether families with the same mutated codon have variable MTC aggressiveness
is not well described. We developed several novel measures of MTC aggressiveness and
compared families with the same mutated codon to determine if there is significant interfamilial variability. Pedigrees of families with MEN2A were reviewed for codon mutated
and proportion of RET mutation carriers with MTC. Individuals with MTC were classified
as having local or distant MTC and whether they had progressive MTC. MTC status and age
were assessed at diagnosis and most advanced MTC stage. For those without MTC, age was
recorded at prophylactic thyroidectomy or last follow-up if the patient did not have a
thyroidectomy. For each pedigree, the mean age of members without MTC, with MTC, and
the proportion of RET mutation carriers with local or distant and progressive MTC were
calculated. We assessed differences in these variables using ANOVA and the Fisher’s exact
test. Sufficient data for analysis were available for families with mutated codons 609 (92
patients from 13 families), 618 (41 patients from 7 families), and 634 (152 patients from 13
families). The only significant differences found were the mean age of patients without
MTC between families with codon 609 and 618 mutations even after accounting for
prophylactic thyroidectomy (p=0.006 and 0.001, respectively), and in the mean age of MTC
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diagnosis between families with codon 618 and 634 mutations even after accounting for
symptomatic presentation (p=0.023 and 0.014, respectively). However, these differences
may be explained by generational differences in ascertainment of RET carriers and the
availability of genetic testing when the proband initially presented.
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ABBREVIATIONS

ATA: American Thyroid Association
CCH: C-cell hyperplasia
MDACC: MD Anderson Cancer Center
MEN2: Multiple Endocrine Neoplasia Type 2
MTC: Medullary Thyroid Cancer
N0MTC: Medullary Thyroid Cancer with No Lymph Node Metastases
N1MTC: Medullary Thyroid Cancer with Lymph Node Metastses
M1MTC: Medullary Thyroid Cancer with Distant Metastases
NED: No Evidence of Disease by Family Report
NEDP: No Evidence of Disease (MTC) on Prophylactic Thyroidectomy
NEDTI: No Evidence of Disease (MTC) with Thyroid Intact
PHEO: Pheochromocytoma
PHPT: Primary Hyperparathyroidism
RET: Rearranged During Transfection Proto-oncogene
TICt: Thyroid Intact with Elevated Calcitonin
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Background
Multiple Endocrine Neoplasia 2A (MEN2A) is an autosomal dominant cancer
predisposition syndrome affecting approximately 1/30,000 people worldwide [1]. It is
characterized by a high risk for medullary thyroid cancer (MTC) as well as risk for
pheochromocytoma (PHEO) and primary hyperparathyroidism (PHPT). The first
presentation and most common cause of morbidity and mortality in MEN2A is MTC, which
affects approximately 90% of patients [2,3]. MTC is a malignant neuroendocrine tumor
comprising approximately 5% of all thyroid cancers but accounting for a disproportionate
number of thyroid cancer-related mortality [4]. It is derived from the parafollicular
calcitonin-producing C-cells of the thyroid and starts as C-cell hyperplasia (CCH) and over
time leads to MTC, which may then metastasize to cervical lymph nodes and distant organs
such as the liver, lungs, and bone [3,5]. The treatment for MTC typically includes a total
thyroidectomy with central neck dissection; additional lymph node dissection may be
performed if metastases are suspected. When local lymph node metastases are present,
treatment is less likely to result in cure, and is typically incurable once spread to distant sites
[2]. Progression of MTC is typically monitored with the aid of serum calcitonin levels,
which increase with volume of MTC and may also be elevated in patients with CCH.
MEN2A is associated with a limited number of recurring germline missense
mutations in the Rearranged During Transfection proto-oncogene (RET). Strong genotypephenotype correlations are well documented, though significant intra- and inter-familial
variability exists [2,6]. The American Thyroid Association (ATA) has categorized all known
MEN2A-causing mutations into three risk levels based on the aggressiveness of MTC
associated with each mutation [2]. These risk levels are used to guide the timing of

2

thyroidectomy in pre-symptomatic MEN2A patients, which greatly reduces the risk for an
advanced thyroid cancer [7,8]. Patients in risk levels A and B may delay surgery beyond five
years of age if the following criteria are met: a normal neck ultrasound, a normal calcitonin
measurement, a less aggressive family history of MTC, and if the family would prefer to
wait. Patients in risk level C are recommended to have a thyroidectomy by age 5 years, with
the specific timing dependent upon the findings of ultrasound and calcitonin levels [2].
While the potential benefits of a prophylactic thyroidectomy are clear, delaying
surgery may be beneficial for children with less-aggressive RET mutations, although this is
controversial [9]. In these patients, MTC before the second decade of life is rare and children
with normal annual calcitonin levels and thyroid ultrasounds are not likely to develop
metastases [2,10]. Children undergoing thyroid surgery have more complications such as
vocal cord paresis and hypocalcemia than adults, especially when they do not have access to
a high-volume surgeon at a multidisciplinary center [9,11]. After surgery, the management
of hormone therapy may be challenging for both the patient and family [9]. These
considerations suggest that delaying prophylactic thyroidectomy may be a valid option for
some patients, though the ideal timing of thyroidectomy and safety of delayed thyroidectomy
is still unclear [3].
Most of the criteria proposed by the ATA for delaying thyroidectomy have been
evaluated with regard to effectiveness of predicting the presence of MTC. Annual serum
calcitonin screening is a powerful method used to screen for MTC and has been validated in
many studies [12,13,14,15]. A serum calcitonin level of less than 40 pg/ml strongly indicates
metastases are not present [8,16]. Limitations of calcitonin screening are also well studied,
and this method may miss early MTCs [17]. Recently, a study evaluating ultrasound in
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pediatric patients with MEN2A concluded it is not a useful method to detect microscopic
MTC and performs with a sensitivity of only 13% [18].
The criterion of a “less aggressive family history” is not well defined. To our
knowledge, no studies have established the relationship between family history of MTC and
MTC outcomes in MEN2 patients independent of genotype. The aim of this study is to
examine intra- and inter-familial variability of MTC within families with the same germline
RET codon mutation.
Methods
Approval from both the University of Texas MD Anderson Cancer Center (MDACC)
and Graduate School of Biomedical Sciences (GSBS) institutional review boards were
obtained for this retrospective chart review.
Participants
Pedigrees of families with MEN2A were acquired through institutional surgical and
genetic counseling databases. Almost all pedigrees were taken by one of three certified
genetic counselors with expertise in MEN2A. According to standard cancer pedigree
nomenclature, information obtained in each pedigree included a minimum of two generations
above the family member interviewed. Targeted questions were asked about each family
member’s history of MTC including the stage, and treatment, genetic testing status, and
whether prophylactic thyroidectomy was performed. Each family member’s age of cancer
diagnosis and current age or age of death was recorded [19].
Pedigrees had at least one MDACC patient and were not separated for related patients
and are updated as patients follow-up. If the pedigree had not been updated within the past
two years, ages were calculated to reflect what was known at last follow-up. We reviewed
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each pedigree for RET mutation positive family members. Any family member with a
diagnosis of MTC, pheochromocytoma, or primary hyperparathyroidism was presumed to be
a RET mutation carrier. Obligate carriers were also recorded as RET mutation carriers. The
proband was defined as the first person diagnosed with MTC.
Each RET mutation carrier was classified by MTC status (figure 1).
Figure 1: RET Mutation Carrier Classification
MTC Status

No MTC

MTC
Diagnosis

Prophylactic
Thyroidectomy

No Metastases

Thyroid Intact:
MDACC
Screening

Local
Metastases

Thyroid Intact:
Family Report

Distant
Metastases

RET mutation carriers were classified into the above groups. Information for
MDACC patients was obtained from the medical record and information about outside
patients was recorded based on family report.

For patients with MTC, MTC status was recorded both at the time of diagnosis and
at the patient’s most advanced MTC stage. Those with an MTC diagnosis were also recorded
as having progressive or non-progressive MTC. Progression was defined as clear
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radiographic growth of MTC, a calcitonin doubling time of less than two years, development
of new metastases, or MTC-related death.
Ages were recorded at the time of prophylactic thyroidectomy or last follow-up if
the patient did not have a thyroidectomy for those without MTC and at the time of MTC
diagnosis and most advanced MTC stage for those with MTC. We also recorded how
patients came to clinical attention and whether they presented due to symptoms of MTC or
through screening due to family history or a positive RET test.
Pedigrees with fewer than four RET mutation carriers, an unknown mutated codon or
variant of uncertain significance (VUS) were excluded. Individuals who tested negative for
the familial RET mutation, whose RET status was unclear, and those who had an intact
thyroid with elevated calcitonin but no clear diagnosis of MTC were excluded from the
study.
Statistical Analysis
The following calculations were performed for each pedigree: (1) mean age and
standard error of RET carriers with no MTC (2) mean age and standard error of MTC
diagnosis (3) proportion of carriers with MTC who had metastases at diagnosis (4)
proportion of carriers with MTC who had metastases at most advanced MTC stage (5)
proportion of carriers with MTC who had disease progression (figure 2).
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Figure 2: Pedigree calculations

Mean Age: MTC-Free
Time of Presentation
or Last Follow-up*

Mean Age: MTC
Diagnosis
Proportion with
Metastases

Approach
Proportion with Metastases
at Most Advanced MTC
Stage
Proportion with MTC
Progression
* Last follow-up applies only to MTC-free patients who have not had a thyroidectomy. The
above calculations were performed for each pedigree. Differences in each variable were
compared between families with the same mutated codon.

Calculations performed at the time of most advanced MTC stage included only
patients seen at MDACC to confirm the diagnosis.
Differences in the mean age of individuals with and without MTC between families
with mutations in the same codon were compared to each other using one-way analysis of
variance (ANOVA) with SPSS21. If the resulting p-value from the ANOVA omnibus test
was <0.05, Tukey’s post-hoc test was used to evaluate all two-way differences. Differences
in proportion of MTC metastases and MTC progression between families with mutations in
the same codon were assessed using Fisher’s exact test using STATA10 software.
Significant differences were achieved if p<0.05.
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Results
A total of 175 pedigrees were reviewed with mutations identified in 11 codons (table
1).
Table 1: Pedigrees Arranged by Mutated Codon and ATA Risk Level
Mutated
Number of
Number of RET
Number of RET
Number of Affected
Codon
Pedigrees Reviewed
Mutation Carriers
Mutation Carriers with
Family Members
(Number Included)
MTC (%)
Included
804
12
---891
5
---666
3
---791*
3
---790
1
---912
1
---891+791*
1
---Total Pedigrees Risk Level A: 26
620
8
---611
2
---609
21 (13)
92
46 (50)
92
618
20 (7)
41
22 (54)
41
Total Pedigrees Risk Level B: 51
634
34 (13)
152
113 (74)
152
Total Pedigrees Risk Level C: 34
Unknown Codon Mutated/ Risk Level: 9
*Patient had bi-allelic RET mutations. Pedigrees with fewer than four affected family members were
excluded from the study.

Due to limitations in the number of families and affected members, comparisons of mean
ages were restricted to codons 609 (92 individuals from 13 families), 618 (41 individuals
from 7 families), and 634 (152 individuals from 13 families) and comparisons of proportions
were limited to codon 634. The median age of all family members, the percent of patients
seen at MDACC, the percent of patients with symptomatic presentation, and the range of
years of first MTC diagnosis representing each codon were recorded (table 2).
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Table 2: Each Codon Represented by Age, Patient Ascertainment, Patient
Presentation and Year of First MTC Diagnosis
Codon 634 Codon 609 Codon 618
Patient Ascertainment
MDACC
94 (62%)
30 (33%)
9 (22%)
Family Report
58 (38%)
62 (67%)
32 (78%)
Patient Presentation
Symptomatic
39 (26%)
17 (18%)
8 (20%)
Screened
113 (74%)
75 (82%)
33 (80%)
Range of First MTC Diagnosis
1944-1992
1970-2011 1969-2001
Range of Ages
2-68
2-79
2-91
Median Age MTC Diagnosis
26
44
37
Median Age MTC-Free
25
28
30
The range and median age in years of family members representing each codon
was recorded.

Patient MTC Status
Overall, 133 patients were MTC-free with 50 having no evidence of MTC upon
prophylactic thyroidectomy, 11 having no evidence of MTC upon screening at MDACC, and
72 having no evidence of MTC based on family report. There were 211 patients with an
MTC diagnosis. Among these patients, 178 had no metastases, 28 had local metastases, and
5 had distant metastases.
Statistical Analyses
Mean Ages
Among families with a mutation in codon 634, differences in mean age of MTC
diagnosis was observed after excluding individuals with symptomatic presentation (p=0.014).
Pedigree 4 had an older age of MTC diagnosis (35.6 years) than pedigree 12 (12.5 years) and
pedigree 68 has an older age of MTC diagnosis (40.6 years) than pedigrees 12 and 102 (5
years, figure 3).
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Figure 3: Mean age of MTC Diagnosis Excluding Individuals With Symptomatic Presentation
for Families with Mutations in Codon 634

Significant differences were found among the average age of MTC diagnosis after excluding
individuals with symptomatic presentation for families with a mutation in codon 634. Pairwise differences are indicated by colored astrices.

Among pedigrees with an older mean age of MTC diagnosis, pedigree 4 is
represented by 9 family members with 6 being in the same generation or a generation above
the proband. Pedigree 68 is represented by family members in the same generation or a
generation above the proband. Among pedigrees with a younger mean age of MTC
diagnosis, both pedigrees 12 and 102 were represented by family members in the same
generation or generations below the proband.
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Significant differences in mean age were found among MTC-free family members
with a mutation in codon 609 (p=0.011) with pedigree 126 having an older mean age (52
years) than pedigree 55 (4 years, figure 4). The difference was maintained after excluding
individuals with prophylactic thyroidectomies (p=0.006). In this analysis, pedigree 5 has an
older mean age (76 years) than pedigrees 131 (23 years), 150 (14 years), and 167 (25 years)
and pedigree 126 has an older mean age (58 years) than pedigree 150 (14 years, figure 4).
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Figure 4: Mean Age of MTC-Free Family Members for Families with Mutations in Codon 609

Significant differences were found among the mean age of MTC-free individuals even after excluding those with prophylactic thyroidectomies for
families with a mutation in codon 609.
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Among pedigrees with an older mean age of MTC-free family members, pedigree
126 is represented by primarily by family members in generations below the proband, but the
familial RET mutation was known in 2008 when the proband’s niece pursued genetic testing
at 64 years of age. Subsequent RET testing and medical intervention identified mutation
carriers who had not yet developed MTC. Pedigree 5 also has an older mean age of MTCfree family members and is represented by family members in the generation above the
proband. All pedigrees with younger mean age of MTC-free family members (55, 131. 150,
and 167) are represented by members in the same generation or generations below the
proband.
Among families with a mutation in codon 618, differences were found among the
mean age of MTC-free family members (p=0.001). None of these individuals had
prophylactic thyroidectomy. Pedigrees 41 and 108 had older mean ages (77 and 64 years,
respectively) than pedigrees 117 and 157 (8 and 7 years, respectively, figure 5).
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Figure 5: Mean Age of MTC-Free Family Members for Families with Mutations in Codon 618

Significant differences were found among the mean age of MTC-free individuals even after excluding those with prophylactic thyroidectomies for
families with a mutation in codon 618.
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A significant difference was found when comparing mean ages of MTC diagnosis
(p=0.036) with pedigree 41 having an older mean age (55 years) than pedigree 119 (20
years). There was still a difference after excluding individuals with symptomatic
presentation (p=0.004) with pedigree 41 having an older mean age (63 years) than pedigrees
117 and 119 (34 and 16 years, respectively, figure 6).
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Figure 6: Mean Age of MTC-Free Family Members for Families with Mutations in Codon 618

Significant differences were found among the mean age of MTC-free individuals even after excluding those with prophylactic thyroidectomies for
families with a mutation in codon 618.
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Pedigree 41 has an older mean age of family members with and without MTC and is
represented by three generations of RET mutation carriers. The first MTC diagnosis dates
back to the mid-1900s, but several MTC diagnoses were not made until genetic testing
became available in the late 1990’s. Pedigree 108 has an older mean age of MTC-free
members and is represented by individuals in generations above the proband.
Among pedigrees with younger mean ages of family members with and without
MTC, all pedigrees (117 and 157 for MTC-free and 117 and 119 for MTC diagnoses) are
represented by individuals in generations below the proband.
Proportion of family members
No differences were found among the proportion of family members with metastases
at presentation or at most advanced MTC stage even after excluding individuals with
symptomatic presentation. No differences were found in the proportion of family members
with MTC progression after excluding individuals with symptomatic presentation even after
excluding individuals with symptomatic presentation (figure 7).
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Figure 7: The Proportion of Family Members with Metastases at Diagnosis and Most Advanced MTC Stage
p=0.341

p=0.389

No differences were found among the proportion of family members with metastases at diagnosis or at most advanced MTC stage. No differences
were found after excluding individuals with symptomatic presentation (p=0.957 at diagnosis, p=.715 at most advanced MTC stage.

18

Discussion
The current study aims to assess if MEN2A kindreds with the same mutated codon have
different family histories from each other based on several novel measures of MTC aggressiveness.
We assessed differences in the mean age of family members with and without MTC controlling for
prophylactic thyroidectomy to determine whether some families have an earlier age of onset of MTC
than others. We assessed differences in the proportion of RET mutation carriers with MTC who had
metastases both at the time of diagnosis and at the time of most advanced MTC stage and the
proportion with MTC progression in an attempt to have a measure of biological aggressiveness of
MTC within each family. Information about patients followed at outside institutions was included to
increase the number of eligible patients and to minimize ascertainment bias.
At first glance, our results suggest that there may be inter-familial variability of MTC age of
onset between kindreds with mutations in the same codon. However, two factors appear to
consistently contribute to inter-familial variability: generational differences in ascertainment of RET
mutation carriers and the availability of genetic testing. Families with a younger mean age of
presentation tend to have a greater proportion of members ascertained in generations below the
proband, while families with an older mean age of presentation are primarily represented by
individuals in generations above the proband. This observation can be appreciated in pedigrees 68
and 102 (figure 8) and suggests that differences in mean age are due to generational differences of
family members in relation to the proband.
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Figure 8: Generational differences in the ascertainment of RET mutation carriers and Mean Age of
MTC Diagnosis

Pedigree 68
Mean Age of MTC
Diagnosis: 40.6 years

Pedigree 102
Mean Age of MTC
Diagnosis: 5.0 years
Note that pedigree 68 has an older mean age of MTC diagnosis and all family members with MTC
are in the same generation or in a generation above the proband. Pedigree 102 has a younger mean
age of MTC diagnosis and all family members with MTC are in generations below the proband.
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It is possible that information about the proband’s MTC diagnosis and/or RET
mutation status is being communicated to family members who opt to have themselves and
subsequently their children screened.
It also appears that some families with an older presentation came to attention before
genetic testing was available. The ages and years of MTC diagnosis for pedigree 41
highlight this observation (figure 9).
Figure 9: The Availability of Genetic Testing and Mean Age of MTC Diagnosis

Pedigree 41
Mean Age of MTC Diagnoses:
63.5 years

Note the years of MTC Diagnoses. Patient 003 did not come to clinical attention until his
sister’s diagnosis of MTC and subsequent RET testing in the mid01990’s. He and his
daughter were found to carry the familial RET mutation and were positive for MTC on
thyroidectomy.
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It also appears that some families with an older presentation came to attention before
genetic testing was available. The ages and years of MTC diagnosis for pedigree 41 highlight
this observation (figure 9). Additionally, this suggests that since genetic testing has become
available, family members are opting to test once a mutation is found in the family, making
young MTC diagnosis likely.
Overall, the current study suggests that apparent differences in the presentation of MTC
between families with the same mutated RET codon are due to ascertainment of family members
in generations older or younger than the proband and the availability of genetic testing as
opposed to true biological differences. To our knowledge, this is the first study attempting to
quantify familial MTC aggressiveness and compare these measures between families with the
same mutated RET codon. The primary limitation is the number of eligible patients. Several
analyses could not be performed including assessing differences in families with mutations in
codons other than 609, 618, and 634. Additionally, many of our analyses were dependent upon
the accuracy of the historian and the genetic counselor as a scribe.
Current MEN2A recommendations state that prophylactic thyroidectomy may be delayed
if certain criteria are met. One criterion is a less aggressive family history of MTC, which
implies that some families have a more aggressive disease course than other with mutations in
the same codon. The results of the current study do not support inter-familial variability between
families with mutations in the same codon based on average age of MTC onset and the
proportion of the family with metastatic disease at diagnosis and most advanced MTC stage.
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